QUILT 3032 study shows efficacy of N-803 in BCG-unresponsive bladder cancer

“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.

Sam S. Chang, MD, MBA, discusses results from the phase 2/3 QUILT-3.032 trial showing the efficacy of the combination of BCG and the novel interleukin-15 superagonist N-803 in patients with BCG-unresponsive bladder cancer.

Chang is a professor in the Department of Urology, Patricia and Rodes Hart Professor of Urologic Surgery, and chief surgical officer and chief of the Division of Urologic Oncology at Vanderbilt Ingram Cancer Center.

Related Videos
Jacob Taylor, MD, MPH, answers a question during a Zoom video interview
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
blur image background of corridor in hospital or clinic image | Image Credit:  © whyframeshot - stock.adobe.com
Urinary bladder | Image credit: © magicmine - stock.adobe.com
Bernard H. Bochner, MD, FACS, answers a question during a Zoom video interview
illustration of bladder cancer
Bernard H. Bochner, MD, FACS, answers a question during a Zoom interview
hospital corridor
Related Content
© 2023 MJH Life Sciences

All rights reserved.